https://www.idival.org/wp-content/uploads/2022/05/cab-presentacion.jpg

Dr Santiago Montes Moreno co-author of a chapter of the WHO blue book on classification of Hematolymphoid Tumors of the Digestive System

8 de July de 2019

The first volume of the 5th edition of the series of the World Health Organization (WHO) on the classification of tumors in humans will be recently published. This series, known as the blue WHO books, is a reference for the diagnosis of neoplasms in different systems and It is an international standard for those involved in […]

Read more →

The group of hematological neoplasms and hematopoietic transplantation of the IDIVAL published a study that linked high levels of the FANCA gene with a worse prognosis in chronic lymphatic leukemia

Chronic Lymphatic Leukemia (CLL) is the most common type of leukemia in adults in the West. It mainly affects elderly patients and its incidence is expected to increase due to the progressive increase in life expectancy in our society. Today is an incurable disease, with a development that can be indolent or more aggressive. Knowing […]

Read more →

Researchers from IDIVAL have studied bacteria resistant to antibiotics isolated in transplanted patients

4 de July de 2019

Patients with solid organ transplants, due to the transplant process itself, hospital admission and immunosuppression, among other factors, are frequently colonized or infected by antibiotic resistant bacteria. In a study published recently in the Scientific Reports journal [doi: 10.1038 / s41598-019-45060-y], IDIVAL researchers belonging to the group of Epidemiology and Pathogenic and Molecular Mechanisms of […]

Read more →

Cerebral molecular image with 11C-PIB PETCT in the evolution of cognitive impairment

24 de June de 2019

Last May, the British journal “Nuclear Medicine Communications” published the work entitled “A 5-year longitudinal evaluation in patients with mild cognitive impairment by 11C-PIB PET / CT: a visual analysis” that gathers results of the longitudinal study that the Service of Nuclear Medicine of the University Hospital Marqués de Valdecilla (HUMV) and the Molecular Imaging […]

Read more →

Valdecilla and IDIVAL discover a genetic variant that protects against Alzheimers and various forms of dementia

16 de June de 2019

Researchers of the Marqués de Valdecilla University Hospital and the Valdecilla Sanitary Research Institute Foundation (IDIVAL) have discovered that a genetic variant in the PLCG2 gene protects against several forms of dementia. According to the results of the study, carried out in collaboration with researchers from the UMC University of Amsterdam, this genetic variation not […]

Read more →

Researchers from IDIVAL and Valdecilla develop for the first time an experimental model for the study of a new variant of the autistic spectrum

11 de June de 2019

The research group “Cell Signalling and Therapeutic Targets in Cancer” of the Valdecilla Health Research Institute Foundation (IDIVAL) and the Marqués de Valdecilla University Hospital have genetically identified a new variant of the autistic spectrum in a pediatric patient by applying techniques of massive sequencing. Known as the ADNP syndrome, the identification of this variant […]

Read more →

Dr Marcos López Hoyos is proclaimed incoming president of the Spanish Society of Immunology

7 de June de 2019

Dr. Marcos López Hoyos, Head of the Immunology Service of the Marqués de Valdecilla University Hospital (Santander, Cantabria) and principal investigator of the Transplant and Autoimmunity IDIVAL group, has been proclaimed incoming President of the SEI (Spanish Society of Immunology).  The result of the elections was 100 votes in favor and 5 votes blank. The […]

Read more →

The European Association for the Study of the Liver rewards a Valdecilla research on chronic cholestatic diseases

14 de May de 2019

Carried out in collaboration with CIC bioGUNE, this study promotes the development of a therapy that attenuates liver injury and slows the progression of these pathologies. A research project of the digestive pathology group of the HUMV and the IDIVAL that paves the way for the development of a therapy that attenuates liver injury and […]

Read more →

IDIVAL broke its patent record in 2018

29 de March de 2019

During 2018 IDIVAL processed 9 patent applications, representing three times the number of applications with respect to the 2013 and previous annuities. Factors such as the promotion of the innovative culture, the certification of the institute by the UNE 166: 002, as well as the incorporation of new specific aids of innovation and technological development […]

Read more →

Diagnosing before the first symptoms

7 de March de 2019

The calcified aortic stenosis (AD) is the third most frequent cardiovascular disease in developed countries, after coronary heart disease and hypertension, with a prevalence of 0.4% in the general population and 1.7% in the population older than 65. It is characterized by progressive thickening and calcification of the valves of the aortic valve that, over […]

Read more →